ACS CAN 2022 Montana Virtual Policy Briefing: Biomarker Testing - The Key to Precision Medicine

Pre-registration has now closed, but you can still join us the day of the event here: acscanbiomarkers.windrosemedia.com

Biomarker testing is growing increasingly important in cancer care, allowing doctors to better understand and tailor treatment to an individual patient’s unique disease. Timely access to appropriate biomarker testing can help achieve better health outcomes, improve quality of life and reduce costs by connecting patients to the most effective treatment for their cancer. Join ACS CAN for a virtual briefing about precision medicine and the importance of expanding access to this testing so that patients across Montana can benefit from the latest advances in treatment. 

Agenda:

Welcome and Introduction, Kristin Page-Nei, Montana Government Relations Director

Biomarker Testing - The Key to Precision Medicine, Connecting patients with the right treatment at the right time - Marielena Mata, Ph.D., Senior Director and Diagnostics Lead, Pfizer

Policy Opportunities to Improve Patient Access to Biomarker Testing, Hilary Gee Goeckner, MSW, Senior State & Local; Campaigns Manager – Access to Care, American Cancer Society Cancer Action Network

The use of the Montana Tumor Registry database to assess Cancer Care in Montana, Jack Hensold, MD, Medical Director of Regional Outreach and consultant to the Montana Cancer Coalition

Close, Kristin Page-Nei

Speakers:

Hilary Gee Goeckner, MSW, Senior State & Local; Campaigns Manager – Access to Care, American Cancer Society Cancer Action Network

Jack Hensold, MD, Medical Oncologist, Consultant, Montana Cancer Coalition

Kristin Page-Nei, Montana Government Relations Director, American Cancer Society Cancer Action Network

Marielena Mata, Ph.D., Senior Director and Diagnostics Lead, Pfizer

Thank you to our partner co-hosts!